Pharming Group (XAMS:PHARM) ROCE %: -2.18% (As of Mar. 2026)


XAMS:PHARM Pharming Group XAMS:PHARM
80 GF Score
Price €1.15
GF Value €1.26
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group ROCE %?

Pharming Group XAMS:PHARM -0.82% 80 ROCE % is -2.18% as of Mar. 2026. GuruFocus rates XAMS:PHARM with a GF Score™ of 80/100 and a GF Value™ of €1.26 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharming Group's annualized ROCE % for the quarter that ended in Mar. 2026 was -2.18%.

Pharming Group  (XAMS:PHARM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharming Group ROCE % Related Terms

Pharming Group ROCE % Historical Data

* Premium members only.

The historical data trend for Pharming Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group ROCE % Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.74 5.86 -1.59 0.07 6.29

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.08 8.03 22.07 6.45 -2.18
XAMS:PHARM
80GF Score
Pharming Group XAMS:PHARM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group ROCE % Calculation

Pharming Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=20.125/( ( (381.986 - 70.481) + (426.968 - 98.886) )/ 2 )
=20.125/( (311.505+328.082)/ 2 )
=20.125/319.7935
=6.29 %

Pharming Group's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-7.12/( ( (426.968 - 98.886) + (423.301 - 97.179) )/ 2 )
=-7.12/( ( 328.082 + 326.122 )/ 2 )
=-7.12/327.102
=-2.18 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -2.18% mean?
Pharming Group (XAMS:PHARM) has a ROCE % of -2.18% as of Mar. 2026.
Is Pharming Group's ROCE % too high?
Pharming Group's current ROCE % is -2.18%. Overall, Pharming Group has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's ROCE % compare to VRTX and REGN?
Pharming Group's ROCE % of -2.18% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Pharming Group's current ROCE % is -2.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (XAMS:PHARM) is currently considered Fairly Valued. The stock's GF Value™ is €1.26, compared to a current price of €1.15 — trading 8.8% below its estimated fair value. The current ROCE % is -2.18%. Pharming Group's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pharming Group (XAMS:PHARM), the current ROCE % is -2.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (XAMS:PHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €1.15 is trading 8.8% below its estimated GF Value™ of €1.26. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for XAMS:PHARM:

  • ROCE %: -2.18%
  • GF Value™: €1.26 vs. price of €1.15 (8.8% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score

Get the complete analysis for XAMS:PHARM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.15
Price
€1.26
GF Value